PMID- 36627146
OWN - NLM
STAT- MEDLINE
DCOM- 20230329
LR  - 20230512
IS  - 2373-2873 (Electronic)
IS  - 2373-2873 (Linking)
VI  - 9
IP  - 1
DP  - 2023 Feb
TI  - A TRIP11:: FLT3 gene fusion in a patient with myeloid/lymphoid neoplasm with 
      eosinophilia and tyrosine kinase gene fusions: a case report and review of the 
      literature.
LID - 10.1101/mcs.a006243 [doi]
LID - a006243
AB  - Myeloid/lymphoid neoplasms with FLT3 gene fusions have recently been included 
      among myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene 
      fusions (MLN-TK) in the World Health Organization classification and 
      International Consensus Classification. As this entity remains remarkably rare, 
      its scope and phenotypic features are evolving. In this report, we describe a 
      33-yr-old male with MLN-TK. Conventional chromosome analysis revealed a 
      t(13;14)(q12;q32). Further analysis with mate-pair sequencing (MPseq) confirmed a 
      TRIP11::FLT3 gene fusion. A diagnosis of MLN-TK was rendered. To the best of our 
      knowledge, we report the third case of MLN-TK with a TRIP11::FLT3 gene fusion. In 
      contrast to previously described cases, our case exhibited distinctly mild 
      clinical features and disease behavior, emphasizing the diverse spectrum of 
      MLN-TK at primary presentation and variability in disease course. MLN-TK with 
      FLT3 gene fusions are a genetically defined entity which may be targetable with 
      tyrosine kinase inhibitors with anti-FLT3 activity. Accordingly, from diagnostic 
      and therapeutic viewpoints, genetic testing for FLT3 rearrangements using 
      fluorescence in situ hybridization (FISH) or sequencing-based assays should be 
      pursued for patients with chronic eosinophilia.
CI  - (c) 2023 Venable et al.; Published by Cold Spring Harbor Laboratory Press.
FAU - Venable, Elise R
AU  - Venable ER
AD  - Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, 
      Mayo Clinic, Rochester, Minnesota 55905, USA.
FAU - Gagnon, Marie-France
AU  - Gagnon MF
AD  - Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine 
      and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA.
FAU - Pitel, Beth A
AU  - Pitel BA
AD  - Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine 
      and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA.
FAU - Palmer, Jeanne M
AU  - Palmer JM
AD  - Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, 
      Phoenix, Arizona 85054, USA.
FAU - Peterson, Jess F
AU  - Peterson JF
AD  - Division of Hematopathology, Department of Laboratory Medicine and Pathology, 
      Rochester, Minnesota 55905, USA.
FAU - Baughn, Linda B
AU  - Baughn LB
AD  - Division of Hematopathology, Department of Laboratory Medicine and Pathology, 
      Rochester, Minnesota 55905, USA.
FAU - Hoppman, Nicole L
AU  - Hoppman NL
AD  - Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine 
      and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA.
FAU - Greipp, Patricia T
AU  - Greipp PT
AD  - Division of Hematopathology, Department of Laboratory Medicine and Pathology, 
      Rochester, Minnesota 55905, USA.
FAU - Ketterling, Rhett P
AU  - Ketterling RP
AD  - Division of Hematopathology, Department of Laboratory Medicine and Pathology, 
      Rochester, Minnesota 55905, USA.
FAU - Patnaik, Mrinal S
AU  - Patnaik MS
AD  - Division of Hematology and Oncology, Department of Medicine Mayo Clinic, 
      Rochester, Minnesota 55905, USA.
FAU - Kelemen, Katalin
AU  - Kelemen K
AD  - Division of Hematopathology, Department of Laboratory Medicine and Pathology; 
      Mayo Clinic, Phoenix, Arizona 85054, USA.
FAU - Xu, Xinjie
AU  - Xu X
AD  - Division of Hematopathology, Department of Laboratory Medicine and Pathology, 
      Rochester, Minnesota 55905, USA; Xu.Xinjie@mayo.edu.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230324
PL  - United States
TA  - Cold Spring Harb Mol Case Stud
JT  - Cold Spring Harbor molecular case studies
JID - 101660017
RN  - 0 (Cytoskeletal Proteins)
RN  - EC 2.7.10.1 (FLT3 protein, human)
RN  - EC 2.7.10.1 (fms-Like Tyrosine Kinase 3)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - 0 (TRIP11 protein, human)
SB  - IM
MH  - Humans
MH  - Male
MH  - Cytoskeletal Proteins/genetics
MH  - *Eosinophilia/genetics
MH  - fms-Like Tyrosine Kinase 3/genetics
MH  - Gene Fusion
MH  - In Situ Hybridization, Fluorescence
MH  - *Lymphoma/genetics
MH  - *Myeloproliferative Disorders/diagnosis/drug therapy/genetics
MH  - Oncogene Proteins, Fusion/genetics
MH  - Protein-Tyrosine Kinases
MH  - Adult
PMC - PMC10111796
OTO - NOTNLM
OT  - eosinophilia
OT  - hematological neoplasm
OT  - malignant eosinophil proliferation
EDAT- 2023/01/11 06:00
MHDA- 2023/03/28 17:11
PMCR- 2023/02/01
CRDT- 2023/01/10 20:52
PHST- 2022/10/25 00:00 [received]
PHST- 2022/12/13 00:00 [accepted]
PHST- 2023/03/28 17:11 [medline]
PHST- 2023/01/11 06:00 [pubmed]
PHST- 2023/01/10 20:52 [entrez]
PHST- 2023/02/01 00:00 [pmc-release]
AID - mcs.a006243 [pii]
AID - 10.1101/mcs.a006243 [doi]
PST - epublish
SO  - Cold Spring Harb Mol Case Stud. 2023 Mar 24;9(1):a006243. doi: 
      10.1101/mcs.a006243. Print 2023 Feb.